Avalo Therapeutics AVTX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $55.01M+74.9% | $50.09M+105% | $45M+148% | $40.92M+316% | $31.45M+218% | ||
| $24.21M+23.5% | $22.9M+32.8% | $21.6M+47.1% | $20.31M+57.6% | $19.59M+81.7% | ||
| $79.22M+55.8% | $72.98M+5.8% | $66.69M+4.7% | $60.6M+11.1% | $50.86M-3.6% | ||
| -$79.16M-57.0% | -$72.93M-6.4% | -$66.49M-5.8% | -$60.16M-11.9% | -$50.42M+1.8% | ||
| $4.01M-8.2% | $4.35M+31.3% | $4.58M+118% | $4.43M+1,169% | $4.36M+278% | ||
| —— | —— | —— | —— | —— | ||
| -$84.57M-216% | -$78.09M-123% | -$99.73M-1,152% | -$46.09M-27.3% | $73.13M+151% | ||
| $169K+47.0% | $165K+44.7% | $149K— | $124K— | $115K— | ||
| -$84.74M-216% | -$78.26M-123% | -$99.88M-1,155% | -$46.22M-27.6% | $73.01M+151% | ||
| -$5.46— | -$5.73— | —— | —— | —— | ||
| -$78.93M-57.4% | -$72.58M-6.2% | -$66.1M-5.4% | -$59.79M-11.5% | -$50.15M+2.0% | ||
| -$79.16M-57.0% | -$72.93M-6.4% | -$66.49M-5.8% | -$60.16M-11.9% | -$50.42M+1.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Avalo Therapeutics's revenue?
- Avalo Therapeutics (AVTX) generated $500.0K in revenue over the trailing twelve months, down 38.0% year over year.
- Is Avalo Therapeutics profitable?
- Avalo Therapeutics is not currently profitable: it reported a net loss of $84.7M over the trailing twelve months, a -7965.8% net margin.
- What are Avalo Therapeutics's profit margins?
- Gross margin is 182.0% and operating margin is -15536.1%, with a -7965.8% net margin.
- What is Avalo Therapeutics's earnings per share?
- Avalo Therapeutics's diluted EPS over the trailing twelve months is $-5.46.
- Where does Avalo Therapeutics's income statement data come from?
- Every line is extracted from Avalo Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
